In general, cancer anti-adhesive immunotherapies have been unsuccessful in contrast with those targeting checkpoint inhibitors such as PD-1 and CTLA-4, which improve sustained T cell activation and show great improvement in some malignant tumors, such as metastatic melanoma (Ribas and Wolchok, 2018). This evidence concerns the gene PDCD1 and cancer.